Summary of Medical Ethics: Charlie Gard Case Study
Medical Ethics: Charlie Gard Case Study Analysis for Students
Introduction
Clinical ethics and experimental treatment examine how ethical principles guide decisions when patients or families seek treatments that are investigational, unproven, or outside standard care. This material explains key concepts used when clinicians, researchers, ethicists and families must decide whether to offer, continue, or stop experimental therapies, and how mediation and institutional oversight shape those decisions.
Definition: Clinical ethics is the field that applies moral principles to patient care decisions; experimental treatment refers to therapeutic interventions that have not completed established preclinical and clinical testing to demonstrate safety and efficacy.
1. Doctor, researcher and their roles
Distinct professional aims
- Doctor (clinician): Duty to the individual patient's best interests, provide evidence-based care, avoid harm, support informed consent and palliation.
- Researcher: Aim to generate generalizable knowledge, follow study protocols, protect participants' rights, and maintain scientific rigor.
Definition: Therapeutic misconception is when a patient (or family) confuses the primary purpose of a clinical trial (knowledge generation) with individualized therapeutic intent.
Overlapping situations
- Clinician-investigators may both treat and enroll patients. Clear role disclosure and conflict-of-interest management are essential.
2. Four principles of medical ethics (applied)
- Autonomy: Respecting patient (or surrogate) decisions after adequate information. For incapacitated patients, surrogates should represent known patient values.
- Beneficence: Acting to benefit the patient — balancing potential benefits of an experimental therapy against its risks.
- Nonmaleficence: Avoiding harm; stopping or refusing treatments that are more likely to harm or offer no real gain.
- Justice: Fair distribution of resources and access; considering societal impacts of offering expensive, unproven treatments.
Definition: Surrogate decision-maker is a person authorized to make healthcare decisions for an incapacitated patient based on prior wishes or best-interest standards.
3. Preclinical and clinical testing overview
Preclinical studies
- Animal models, in vitro experiments, toxicology studies — establish plausibility and safety signals before human exposure.
Clinical trial phases (concise)
- Phase I: Safety and dosing in small numbers of humans.
- Phase II: Preliminary efficacy and further safety.
- Phase III: Large trials to confirm efficacy and monitor adverse events.
- Phase IV: Post-marketing surveillance.
Definition: Investigational Medicinal Product (IMP) is a pharmaceutical form of an active substance being tested or used as a reference in a clinical trial.
Rules and safeguards
- Institutional Review Board (IRB) / Ethics Committee approval required before human studies.
- Informed consent must be documented; additional protections for vulnerable populations.
- Monitoring and stopping rules for safety.
4. Experimental therapy vs. clinical trial participation
- Experimental therapy given off-protocol to an individual differs from enrolling the individual in a clinical trial: the former lacks systematic data collection and oversight designed to produce generalizable knowledge.
- Key considerations when offering experimental therapy: biological plausibility, prior preclinical/clinical evidence, risk/benefit ratio, and alternatives (including palliative care).
Table: Experimental therapy vs. Clinical trial
| Feature | Experimental therapy (individual) | Clinical trial participation |
|---|---|---|
| Primary goal | Individual benefit | Knowledge generation and benefit for |
Sign up for the full summaryAlready have an account? Sign in
Clinical Ethics & Experimental Treatment
Klíčové pojmy: Distinguish clinician (individual care) from researcher (knowledge generation)., Obtain IRB/Ethics Committee approval for clinical research; compassionate use has additional safeguards., Apply the four principles: autonomy, beneficence, nonmaleficence, justice., Define futility: physiologic vs qualitative futility before stopping treatments., Use time-limited trials with predefined goals when uncertainty exists., Palliative care must be offered alongside or instead of futile experimental therapies., Clinical ethicists mediate disputes by clarifying facts and values and facilitating consensus., Evaluate distributive justice: consider opportunity costs and equity when offering expensive experimental treatments., Avoid therapeutic misconception by explaining the primary goal of trials versus individual therapy., Document decisions, second opinions, and communications thoroughly., Use transparent communication techniques: plain language, validate emotions, explain uncertainties., Social media and crowdfunding can create undue pressure; clinicians should follow institutional policies.